Diabetes in Japan: a review of disease burden and approaches to treatment

Abstract

In recent years there has been rapid growth in diabetes in Japan which now is one of the nations most affected by the worldwide diabetes epidemic. Diabetes has been identified as a healthcare priority by the Ministry of Health, Labour and Welfare (MHLW). Type 1 diabetes is rare in Japan, and type 2 diabetes predominates in both adults and children. The growth in diabetes is due to increases in the number of people with type 2 diabetes associated with increased longevity and lifestyle changes. Approximately 13.5% of the Japanese population now has either type 2 diabetes or impaired glucose tolerance. This high prevalence of type 2 diabetes is associated with a significant economic burden, with diabetes accounting for up to 6% of the total healthcare budget. The costs of diabetes are increased in patients with co-morbidities such as hypertension and hyperlipidaemia and in patients who develop complications, of which retinopathy has the highest cost. Costs increase with increasing number of complications. Current guidelines from the Japan Diabetes Society (JDS) recommend a target HbA(1c) of 6.5% for glycaemic control. This is achieved in approximately one third of patients with type 2 diabetes, and Japanese patients typically have lower HbA(1c) than patients in Western countries (e.g. US, UK). Japanese patients with type 2 diabetes have better adherence with diet and exercise recommendations than their peers in Western countries. Sulfonylureas have been the most widely prescribed first-line treatment for type 2 diabetes, although there is increasing use of combination therapy and of insulin.

The Relationship Between Low-Density Lipoprotein Cholesterol Levels and the Incidence of Cardiovascular Disease in High-Risk Patients Treated With Pravastatin

“…The results showed that the incidence of cardiovascular disease decreases as more risk factor targets are achieved. (The targets are defi ned by the guidelines of the JAS, 14) Japan Society of Hypertension, 37) and Japan Diabetes Society 38) ). These results indicate that patients who achieve low LDL-C and concurrently have good blood pressure and glucose control, as well as good 0.690 *Achievement of risk factor targets was defi ned by using mean values during follow-up according to the following criteria: low-density lipoprotein cholesterol < 120 mg/dL, blood pressure < 130/80 mmHg, hemoglobin A1c (US National Glycohemoglobin Standardization Program) < 6.5%, and no smoking during follow-up.…”

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, suppresses CXCL5 and SDF-1 and does not accelerate intestinal neoplasia formation in ApcMin/+ mice fed a high-fat diet

“…It is well known that morbid obesity is associated with insulin resistance and can increase the risk for developing diabetes mellitus type 2 (1,2). Consistent with these changes, the rates of pancreatic, colon, prostate and breast cancers, which are more frequent in Western nations, have increased in Japan (2-4).…”

Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus

“…Japan was ranked among the top 10 countries in a global survey of the numbers of people aged between 20 and 79 years with diabetes, and the prevalence of the disease in the Japanese population increased by more than 4% between 2000 and 2010 2,3 . Type 2 diabetes mellitus accounts for the majority of cases of diabetes in Japan 4 . Most patients with type 2 diabetes mellitus fail to attain and maintain glycemic targets with current therapies 5 .…”